IP Library › Granted Patent US 12,533,342
Granted Patent B2
US 12,533,342 · App. 17/826,712 · Granted Jan 27, 2026

Methods of treating bacterial infections

Inventors: Elizabeth Alexander (Maplewood, NJ); Jeffrey S. Loutit (Los Altos, CA); Michael N. Dudley (San Diego, CA)
Assignee: MELINTA SUBSIDIARY CORP.
A61K31/407A61K9/0019A61K31/69A61P31/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,533,342
App. No.
17/826,712
Granted
Jan 27, 2026
Kind
B2
Abstract

Methods of treating bacterial infection in immunocompromised subjects and subjects with one or more underlying malignancies include administering a combination of meropenem and vaborbactam to the subject. Suitable subjects to be treated can include a subject with a history of ongoing leukemia or lymphoma, a subject that has had an organ transplant, stem cell transplant, bone marrow transplant, or splenectomy, a subject receiving immunosuppressive medications, a subject receiving bone marrow ablative chemotherapy, a subject with neutropenia and subject suffering from or having suffered from a malignancy.

Claims (16)

1 . A method of therapeutically treating one or more bacterial infection in a subject, wherein the subject is immunocompromised, comprising administering to the subject in need thereof a combination of meropenem and vaborbactam, wherein the subject achieves a maximum post baseline creatinine increase of <0.5 mg/dL.

2 . The method of claim 1 , wherein the bacterial infection is selected from the group consisting of Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Enterobacter cloacae species complex, Enterococcus faecium, Serratia marcescens, Streptococcus pyogenes, Streptococcus pneumoniae, Haemophilus influenzae, Chlamydia trachomatis, Mycoplasma pneumoniae, Legionella pneumophila, Acinetobacter baumannii, Bartonella bacilliformis, Brucella species, Calymmatobacterium granulomatis, Campylobacter fetus, Francisella tularensis, Haemophilus ducreyi, Vibrio cholerae , and Yersinia pestis.

3 . The method of claim 1 , wherein the subject has a history of ongoing leukemia or lymphoma.

4 . The method of claim 1 , wherein the subject has had an organ transplant, stem cell transplant, bone marrow transplant, or splenectomy.

5 . The method of claim 1 , wherein the subject is receiving immunosuppressive medications.

6 . The method of claim 1 , wherein the subject is receiving bone marrow ablative chemotherapy.

7 . The method of claim 1 , wherein the subject has neutropenia.

8 . The method of claim 1 , wherein the subject is suffering from or has suffered from a malignancy.

9 . The method of claim 1 , wherein the subject has an absolute neutrophil count below about 1000 cells/mm 3 .

10 . The method of claim 1 , wherein the administration is oral, intravenous, intraperitoneal, intragastric, or intravascular administration.

11 . The method of claim 1 , wherein the dose of the meropenem administered is between 1 mg and 5000 mg and the dose of the vaborbactam administered is between 1 mg and 5000 mg.

12 . The method of claim 11 , wherein the dose of meropenem is 10 mg to 3000 mg and the dose of vaborbactam is 10 mg to 3000 mg.

13 . The method of claim 11 , wherein the dose of meropenem is 100 mg to 2000 mg and the dose of vaborbactam is 100 mg to 2000 mg.

14 . The method of claim 1 , wherein the meropenem and vaborbactam are administered in a weight ratio from 2:1 to 1:2.

15 . The method of claim 1 , wherein the meropenem and the vaborbactam are administered from one to four times daily, and wherein the meropenem and vaborbactam are administered from about 1 day to at least about 4 weeks.

16 . The method of claim 1 , wherein the meropenem and vaborbactam are administered simultaneously.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 11, 2025
From: ALEXANDER, ELIZABETH; LOUTIT, JEFFREY S.; DUDLEY, MICHAEL N.
To: REMPEX PHARMACEUTICALS, INC.
Reel/Frame 072861/0302 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 11, 2025
From: REMPEX PHARMACEUTICALS, INC.
To: MELINTA THERAPEUTICS, INC.
Reel/Frame 072861/0385 →
CHANGE OF NAME Recorded Nov 11, 2025
From: MELINTA THERAPEUTICS, INC.
To: MELINTA SUBSIDIARY CORP.
Reel/Frame 072861/0454 →
TERMINATION AND RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT (PATENTS) AT REEL 054836 AND FRAME 0824, REEL 061314 AND FRAME 0572 AND REEL 068260 AND FRAME 0283 Recorded Aug 29, 2025
From: SILICON VALLEY BANK, A DIVISION OF FIRST-CITIZENS BANK & TRUST COMPANY
To: MELINTA SUBSIDIARY CORP.
Reel/Frame 074576/0471 →
AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Aug 25, 2022
From: MELINTA SUBSIDIARY CORP.
To: SILICON VALLEY BANK
Reel/Frame 061314/0572 →
Continuity (4)
Continuation 16753288
Provisional Application 62657402 · Apr 13, 2018
Provisional Application 62567702 · Oct 3, 2017
Related Publication 20220288024A1 · Sep 15, 2022
References Cited (63)
US 11376237B2 · Alexander · 2022 [cited by examiner]
US 20120040932A1 · Hirst et al. · 2012 [cited by applicant]
US 20130331355A1 · Griffith et al. · 2013 [cited by applicant]
US 20160113921A1 · Kapsner et al. · 2016 [cited by applicant]
US 20170065626A1 · Bonomo et al. · 2017 [cited by applicant]
CN 102188395A · 2011 [cited by applicant]
CN 102335136A · 2012 [cited by applicant]
CN 102335137A · 2012 [cited by applicant]
CN 102525961A · 2012 [cited by applicant]
CN 104337765A · 2015 [cited by applicant]
WO WO2012021455A1 · 2012 [cited by applicant]
WO WO20130184845A1 · 2013 [cited by applicant]
WO WO2014019282A1 · 2014 [cited by applicant]
WO WO20160172208A1 · 2016 [cited by applicant]
WO WO2017008034A1 · 2017 [cited by applicant]
WO WO2018129479A1 · 2018 [cited by applicant]
WO WO2019070591A1 · 2019 [cited by applicant]
Zar. Thorax, 2013, 68, 1052-1056 (Year: 2013). [cited by examiner]
Poll. Lancet, 2009, 374, 1549-56 (Year: 2009). [cited by examiner]
Debnath. Annals of Pharmacology, 2023, 57 (7), 803-812 (Year: 2023). [cited by examiner]
Examination Report issued Dec. 9, 2024 by Indonesian Patent Office in Indonesian Patent Application No. P00202003200 with English translations (8 total pages). [cited by applicant]
Wunderink, R.G., et al., Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The Tango II Randomized Clinical Trial, Infect. Dis.… [cited by applicant]
Paterson, D., et al., “Meropenem-Vaborbactam (Vabomere) vs. Best Available Therapy for Carbapenem-Resistant Enterobacteriaceae Infections in Tango II: Outcomes in Immunocompromised Patients,” Poster presented at IDWeek … [cited by applicant]
Fingl, E. and Woodbury, D.W., “Section 1, Introduction—Chapter 1, General Principles,” The Pharmacological—Basis of Therapeutics, Fifth Edition, edited by Goodman, L.S., et al., Macmillan Publishing Co., Inc., New York,… [cited by applicant]
Menzo, S.L., et al., “New Insight on Epidemiology and Management of Bacterial Bloodstream Infection in Patients with Hematological Malignancies” (Review Article), Mediterr. J. Hematol. Infect. Dis., vol. 7, No. 1, e2015… [cited by applicant]
Castanheira, N., et al., “Meropenem-Vaborbactam Activity against Enterobacteriaceae Isolates, Including Carbapenem-Resistant and Carbapenemase-Producing Isolates, Collected in United States (US) Hospitals During 2016” (… [cited by applicant]
International Search Report and Written Opinion mailed Nov. 30, 2018 by Australian Patent Office as International Searching Authority in International Patent Application No. PCT/US2018/053772 (9 total pages). [cited by applicant]
McCarthy, M.W. and Walsh, T.J., “Meropenem/vaborbactam fixed combination for the treatment of patients with complicated urinary tract infections,” Drugs of Today, vol. 53, No. 10, pp. 521-530 (2017). [cited by applicant]
No Author, U.S. Food and Drug Administration label for Vabomere™, manufactured by Facta Farmaceutici, S.p.A. and marked by The Medicines Company, 24 total pages (initial U.S. Approval: 2017). [cited by applicant]
Hecker, S.J., et al., “Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases,” J. Med. Chem., vol. 58, pp. 3682-3692 (Mar. 17, 2015). [cited by applicant]
Patriarca, F., et al., “Risk Factors and Outcomes of Infections by Multidrug-Resistant Gram-Negative Bacteria in Patients Undergoing Hematopoietic Stem Cell Transplantation,” Biol. Blood Marrow Transplant, vol. 23, pp. … [cited by applicant]
Wang, Q., et al., “Risk factors and clinical outcomes for carbapenein-resistant Enterobacteriaceae nosocomial infections,” Eur. J. Clin. Microbial. Infect. Dis., vol. 35, pp. 1679-1689 (published online Jul. 11, 2016). [cited by applicant]
Castanheira, M., et al., “Meropenem-Vaborbactam Tested against Contemporary Gram-Negative Isolates Collected Worldwide during 2014, Including Carbapenem-Resistant, KPC-Producing, Multidrug-Resistant, and Extensively Dru… [cited by applicant]
Office Action issued May 20, 2022 by Saudi Authority for Intellectual Property in Saudi Arabian Patent Application No. 520411705 with English translation (7 total pages). [cited by applicant]
Office Action issued Jul. 4, 2022 by Mexican Institute of Industrial Property in Mexican Patent Application No. MX/a/2020/003670 with English translation (8 total pages). [cited by applicant]
No Author, “A Phase 3, Multi-center, Randomized, Open-Label Study of Carbavance (Meropenem/RPX7009) versus Best Available Therapy in Subjects with Selected Serious Infections due to Carbapenem-Resistant Enterobacteriace… [cited by applicant]
Office Action issued Jul. 21, 2022 by Colombian Superintendence of Industry and Commerce in Colombian Patent Application No. NC2020/0005419 with English translation (33 total pages). [cited by applicant]
Office Action issued Sep. 5, 2022 by Taiwanese Patent Office in Taiwanese Patent Application No. 107134824 with English translation (9 total pages). [cited by applicant]
Castanheira, M., et al., “Effect of the beta-Lactamase Inhibitor Vaborbactam Combined with Meropenem against Serine Carbapenemase-Producing Enterobacteriaceae,” Antimicrobial Agents and Chemotherapy, vol. 60, No. 9, pp.… [cited by applicant]
Notice of Reasons for Rejection issued Oct. 5, 2022 by Japanese Patent Office in Japanese Patent Application No. 2020-519066 with English translation (6 total pages). [cited by applicant]
Office Action issued Nov. 28, 2022 by Chinese Patent Office in Chinese Patent Application No. 201880072552.X with English translation (9 total pages). [cited by applicant]
Office Action issued Feb. 21, 2023 by Mexican Patent Office in Mexican Patent Application No. MX/a/2020/003670 with English translation (14 total pages). [cited by applicant]
Castanheira, M., et al., “Meropenem-Vaborbactam Activity against Carbapenem-Resistant Enterobacterales Isolates Collected in U.S. Hospitals during 2016 to 2018,” Antimicrob. Agents Chemother., vol. 64, No. 2, e01951-19,… [cited by applicant]
Communication pursuant to Article 94(3) EPC issued Apr. 12, 2023 by European Patent Office in European Patent Application No. 18863923.1 (5 total pages). [cited by applicant]
No Author, “Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults with cUTI and AP,” sponsored by Melinta Therapeutics, Inc., ClinicalTrials.gov Identifier: NCT02166476, 14 total pages (… [cited by applicant]
Notice of Reasons for Rejection issued May 29, 2023 by Japanese Patent Office in Japanese Patent Application No. 2020-519066 with English translation (8 total pages). [cited by applicant]
Substantive Examination Report issued Jun. 27, 2023 by Intellectual Property Office of the Philippines in Filipino Patent Application No. 1/2020/550249 (5 total pages). [cited by applicant]
Rejection Decision issued Jul. 6, 2023 by Taiwanese Patent Office in Taiwanese Patent Application No. 107134824 with English summary (6 total pages). [cited by applicant]
Examination Report issued Aug. 9, 2023 by Thai Patent Office in Thai Patent Application No. 2001001955 with English translation (8 total pages). [cited by applicant]
Office Action issued Sep. 27, 2023 by Chinese Patent Office in Chinese Patent Application No. 201880072552.X with English translation (8 total pages). [cited by applicant]
Examination Report issued Oct. 5, 2023 by Australian Patent Office in Australian Patent Application No. 2018345317 (6 total pages). [cited by applicant]
Notice of Preliminary Rejection issued Oct. 20, 2023 by Korean Intellectual Property Office in Korean Patent Application No. 10-2020-7012784 with English translation (13 total pages). [cited by applicant]
Substantive Examination Clear Report—Section 30(1) issued Oct. 22, 2023 by Intellectual Property Corporation of Malaysia in Malaysian Patent Application No. PI2020001141 (2 total pages). [cited by applicant]
Rejection Ruling issued Dec. 5, 2023 by Chilean Patent Office in Chilean Patent Application No. 2020-00892 with English translation (8 total pages). [cited by applicant]
Office Action issued Dec. 18, 2023 by United Arab Emirates (“UAE”) Patent Office in UAE Application No. P6000488/2020 (9 total pages). [cited by applicant]
“ [cited by applicant]
Decision of Rejection issued Mar. 1, 2024 by China National Intellectual Property Administration in Chinese Patent Application No. 201880072552.X with English translation (11 total pages). [cited by applicant]
Office Action issued Mar. 6, 2024 by Canadian Intellectual Property Office in Canadian Patent Application No. 3078238 (4 total pages). [cited by applicant]
Notification of Result of Substantive Examination issued Mar. 13, 2024 by Intellectual Property of Office of Indonesia in Indonesian Patent Application No. P00202003200 with English Translation (8 total pages). [cited by applicant]
Communication pursuant to Article 94(3) EPC issued Jul. 24, 2024 by European Patent Office in European Patent Application No. 18863923.1 (4 total pages). [cited by applicant]
Subsequent Substantive Examination Report issued Sep. 10, 2024 by Filipino Patent Office in Filipino Patent Application No. 1/2020/550249 (5 total pages). [cited by applicant]
Examination Report issued Sep. 16, 2024 by Australian Patent Office in Australian Patent Application No. 2018345317 (3 total pages). [cited by applicant]
Notice of Final Rejection issued Oct. 24, 2024 by Korean Patent Office in Korean Patent Application No. 10-2020-7012784 with English translation (9 total pages). [cited by applicant]